BridgeMD
New treatment option for Glaucoma
Official title Ocular Blood Flow Imaging for Glaucoma Assessment
ClinicalTrials.gov ID: NCT05726058
What this study is testing
- What it's testing
- The goal of this clinical trial is to investigate the use of an FDA-cleared retinal blood flow imaging instrument called the XyCAM RI and XyCAM FC (Vasoptic Medical, Inc., Columbia, MD) in glaucoma management. The main question it aims to answer are: Can the investigators use blood flow to discriminate between eyes with early-stage glaucoma and variable-matched controls?
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 88. Healthy volunteers may be eligible.
You may be able to join if
- Age 18 and older with binocular vision
- Able to provide informed consent
- Patient is a healthy control OR is recommended for glaucoma assessment OR diagnosed with moderate to severe glaucoma in at least one eye as...
You likely can't join if
- The subject has significant media opacity (e.g., a visually significant cataract or significant corneal scar)
- The subject has previous ocular surgery other than uncomplicated cataract extraction, laser trabeculoplasty (ALT or SLT), or YAG capsulotomy
- The subject has prior ocular disease other than glaucoma
- The subject has anatomically narrow angles or a prior adverse reaction to administration of Tropicamide or fluorescein dye
- The subject has more than 15 diopters of refractive error
- The subject is a female who is pregnant or nursing
See the full eligibility criteria
- Age 18 and older with binocular vision
- Able to provide informed consent
- Patient is a healthy control OR is recommended for glaucoma assessment OR diagnosed with moderate to severe glaucoma in at least one eye as determined by Hodapp Anderson Criteria
- The subject has significant media opacity (e.g., a visually significant cataract or significant corneal scar)
- The subject has previous ocular surgery other than uncomplicated cataract extraction, laser trabeculoplasty (ALT or SLT), or YAG capsulotomy
- The subject has prior ocular disease other than glaucoma
- The subject has anatomically narrow angles or a prior adverse reaction to administration of Tropicamide or fluorescein dye
- The subject has more than 15 diopters of refractive error
- The subject is a female who is pregnant or nursing
- The subject has diabetes mellitus
The study team makes the final eligibility decision.
Where it's taking place
- Baltimore, Maryland, United States
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 88 years. Healthy volunteers may be eligible. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Baltimore, Maryland, United States. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.